| 42.07 -1.06 (-2.46%) | 11-29 13:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 50.96 |
1-year : | 55.81 |
| Resists | First : | 43.63 |
Second : | 47.79 |
| Pivot price | 40.31 |
|||
| Supports | First : | 36.91 |
Second : | 30.71 |
| MAs | MA(5) : | 42.28 |
MA(20) : | 40.98 |
| MA(100) : | 49.69 |
MA(250) : | 52.13 |
|
| MACD | MACD : | -0.8 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 79.1 |
D(3) : | 67.4 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 70.12 | Low : | 36.91 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LEGN ] has closed below upper band by 23.3%. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 43.59 - 43.8 | 43.8 - 43.99 |
| Low: | 41.22 - 41.45 | 41.45 - 41.67 |
| Close: | 42.74 - 43.11 | 43.11 - 43.46 |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Sun, 01 Dec 2024
Bellevue Group AG Lowers Position in Legend Biotech Co. (NASDAQ:LEGN) - MarketBeat
Sat, 30 Nov 2024
Braidwell LP Lowers Stock Holdings in Legend Biotech Co. (NASDAQ:LEGN) - MarketBeat
Fri, 29 Nov 2024
125,000 Shares in Legend Biotech Co. (NASDAQ:LEGN) Bought by Vestal Point Capital LP - MarketBeat
Wed, 27 Nov 2024
Why Is Legend Biotech Corp. (LEGN) Among the Best Up and Coming Stocks to Buy According to Analysts? - Yahoo Finance
Thu, 21 Nov 2024
Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance
Fri, 15 Nov 2024
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 183 (M) |
| Shares Float | 163 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 51.2 (%) |
| Shares Short | 15,860 (K) |
| Shares Short P.Month | 12,070 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.07 |
| Profit Margin | -67 % |
| Operating Margin | -44 % |
| Return on Assets (ttm) | -12.3 % |
| Return on Equity (ttm) | -28.4 % |
| Qtrly Rev. Growth | 66.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.83 |
| EBITDA (p.s.) | -1.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -158 (M) |
| Levered Free Cash Flow | -120 (M) |
| PE Ratio | -21.92 |
| PEG Ratio | 0 |
| Price to Book value | 6.91 |
| Price to Sales | 14.83 |
| Price to Cash Flow | -48.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|